Spotlight Poster Discussion 13 – Friday, December 10, 2021: 7:00 am – 8:30 am CT
   
  Novel Therapeutics
PD13-01 Balixafortide (a CXCR4 antagonist)+eribulin versus eribulin alone in patients with HER2 negative, locally recurrent or metastatic breast cancer: An international, randomized, phase 3 trial (FORTRESS)
Kaufman P, Martin M, Mayer I, Vahdat L, Pernas S, Schmid P, McArthur H, Dent R, Rugo HS, Barrios C, Bobirca A, Ringeisen F, Schmitter D, Cortes J. University of Vermont Cancer Center, Burlington, VT; Hospital General Universitario Gregorio Marañón, Madrid, Spain; Vanderbilt University Medical Center, Nashville, TN; Memorial Sloan Kettering Cancer Center, New York, NY; Institut Català d’Oncologia,L’Hospitalet, Barcelona, Spain; Queen Mary University of London, London, United Kingdom; Cedars-Sinai, Los Angeles, CA; National Cancer Center Singapore, Singapore, Singapore; University of California San Francisco, San Francisco, CA; Centro de Pesquisa em Oncologia, Hospital São Lucas, PUCRS, Porto Alegre, Brazil; Polyphor Ltd, Allschwil, Switzerland; International Breast Cancer Center (IBCC), Institute of Oncology, Quironsalud Group, Madrid & Barcelona and Vall d´Hebron Institute of Oncology (VHIO), Barcelona, Spain.
PD13-02 Phase Ib expansion study of gedatolisib in combination with palbociclib and endocrine therapy in women with ER+ metastatic breast cancer
Layman R, Wesolowski R, Han H, Specht JM, Stringer-Reasor EM, Dees EC, Kabos P, Mayer IA, Vaishampayan U, Lu J, Gogineni K, Bardia A, Schott AF, Abu-Khalaf M, Howkins D, Sullivan B, Gorbatchevsky I, Rugo H. The University of Texas MD Anderson Cancer Center, Houston, TX; James Cancer Hospital and the Ohio State University Comprehensive Cancer Center, Columbus, OH; Moffit Cancer Center, Tampa, FL; Fred Hutch University of Washington Cancer Consortium, Seattle, WA; University of Alabama, Birmingham, AL; UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC; University of Colorado Hospital- Anschutz Caner Pavilion (ACP), Aurora, CO; Vanderbilt University Medical Center, Vanderbilt-Ingram Cancer Center, Nashville, TN; Karmanos Cancer Institute, Detroit, MI; USC Norris Comprehensive Cancer Center, Los Angeles, CA; Emory University Hospital, Atlanta, GA; Massachusetts General Hospital, Harvard Medical School, Boston, MA; University of Michigan, Ann Arbor, MI; Sidney Kimmel Cancer Center at Jefferson Health, Philadelphia, PA; Celcuity, Minneapolis, MN; University of California San Francisco Comprehensive Cancer Center, San Francisco, CA.
PD13-03 Ribociclib, everolimus, exemestane triplet therapy in HR+/HER2− advanced breast cancer after progression on a CDK4/6 inhibitor: Final efficacy, safety, and biomarker results from TRINITI-1
Hurvitz SA, Clark AS, Rugo HS, Bardia A, Zelnak A, Yardley DA, Karuturi M, Sanft T, Blau S, Hart L, Ma C, Purkayastha D, Eppig C, DeMichele A. UCLA Jonsson Comprehensive Cancer Center, Los Angeles, CA; University of Pennsylvania Abramson Cancer Center, Philadelphia, PA; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA; Northside Hospital Cancer Institute, Atlanta, GA; Sarah Cannon Research Institute and Tennessee Oncology, Nashville, TN; The University of Texas MD Anderson Cancer Center, Houston, TX; Yale University School of Medicine, New Haven, CT; Northwest Medical Specialties, Puyallup, WA; Florida Cancer Specialists, Fort Myers, FL; Washington University School of Medicine, St. Louis, MO; Novartis Pharmaceuticals Corporation, East Hanover, NJ.
PD13-04 Activity of patritumab deruxtecan, a HER3-directed antibody drug conjugate, in early breast cancer according to ERBB3 expression: Interim analysis results of a window-of-opportunity study (SOLTI-1805 TOT-HER3)
Prat A, Cejalvo JM, Pare L, Martínez-Sáez O, Margelí Vila M, Falato C, Cruz J, Arumí de Dios M, Vidal MJ, Guerra JA, Luna Barrera AM, Tolosa P, Salvador-Bofill FJ, Pernas S, Gonzáles-Farré B, Sanfeliu E, Ciruelos E, Serra V, Espinosa-Bravo M, Izarzugaza Y, Esker S, Fan P-D, Villacampa G, Ferrero-Cafiero JM, Pascual T, Oliveira M. SOLTI Innovative Cancer Research/Medical Oncology Department, Hospital Clinic/Translational Genomics and Targeted Therapies in Solid Tumors, August Pi i Sunyer Biomedical Research Institute/Medicine Department, University of Barcelona, Barcelona, Spain; Medical Oncology Department, Hospital Clínico Universitario de Valencia/Breast Cancer Biology Research Group, Biomedical Research Institute INCLIVA, Valencia, Spain; SOLTI Innovative Cancer Research, Barcelona, Spain; Medical Oncology Department, Hospital Clinic/Translational Genomics and Targeted Therapies in Solid Tumors, August Pi i Sunyer Biomedical Research Institute/Medicine Department, University of Barcelona, Barcelona, Spain; SOLTI Innovative Cancer Research/Medical Oncology Department, ICO - Institut Català d' Oncologia Badalona (Hospital Universitario Germans Trias i Pujol), Barcelona, Spain; SOLTI Innovative Cancer Research/Medical Oncology Department, Hospital Clinic/Translational Genomics and Targeted Therapies in Solid Tumors, August Pi i Sunyer Biomedical Research Institute, Barcelona, Spain; Medical Oncology Department, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain; Medical Oncology Department, Vall d'Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d’Hebron, Vall d’Hebron Barcelona Hospital Campus, Barcelona, Spain; Medical Oncology Department, Hospital Universitario de Fuenlabrada, Madrid, Spain; Medical Oncology Department, Centro Integral Oncológico Clara Campal, Madrid, Spain; SOLTI Innovative Cancer Research/Medical Oncology Department, Hospital 12 de Octubre, Madrid, Spain; Medical Oncology Department, Hospital Universitario Virgen del Rocio, Sevilla, Spain; SOLTI Innovative Cancer Research/Medical Oncology Department, Institut Catala d' Oncologia (ICO), H. U. Bellvitge-Institut d'Investigació Biomèdica de Bellvitge, Barcelona, Spain; SOLTI Innovative Cancer Research/Translational Genomics and Targeted Therapies in Solid Tumors, August Pi i Sunyer Biomedical Research Institute/Pathology Department, Hospital Clinic, Barcelona, Spain; Medical Oncology Department, Vall d'Hebron Institute of Oncology (VHIO), Vall d’Hebron Barcelona Hospital Campus/Breast Cancer Program, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital, Barcelona, Spain; Breast Cancer Surgical Unit, Vall d' Hebron University Hospital, Barcelona, Spain; Medical Oncology Department, Fundación Jimenez Díaz, Madrid, Spain; Research and Development, Daiichi Sankyo, Inc., Basking Ridge, NJ; SOLTI Innovative Cancer Research/Oncology Data Science, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; SOLTI Innovative Cancer Research/Medical Oncology Department, Vall d'Hebron Institute of Oncology (VHIO), Vall d’Hebron Barcelona Hospital Campus/Breast Cancer Program, Vall d'Hebron Institute of Oncology (VHIO),Vall d'Hebron Barcelona Hospital, Barcelona, Spain.
PD13-05 Alpelisib + fulvestrant in patients with PIK3CA-mutated, HR+, HER2— advanced breast cancer (ABC) who received chemotherapy or endocrine therapy (ET) as immediate prior treatment: BYLieve Cohort C primary results and exploratory biomarker analyses
Rugo HS, Neven P, Saffie I, Park YH, De Laurentiis M, Lerebours F, Ciruelos EM, Turner N, Juric D, Gu E, Arce CH, Joshi M, Roux E, Akdere M, Chia S. UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, CA; University Hospitals, Leuven, Belgium; Centro de Investigación Clínica Bradford Hill and Fundación Arturo López Pérez, Santiago, Chile; Samsung Medical Center, Sungkyunkwan University, Seoul, Republic of Korea; Dept. of Breast and Thoracic Oncology, IRCCS Istituto Nazionale Tumori “Fondazione G. Pascale”, Napoli, Italy; Institut Curie, Saint-Cloud, France; Hospital Universitario 12 de Octubre, Madrid, Spain; The Royal Marsden and Institute of Cancer Research, London, United Kingdom; Massachusetts General Hospital Cancer Center, Boston, MA; Novartis Pharmaceuticals Corporation, East Hanover, NJ; Novartis, East Hanover, NJ; Novartis Pharma AG, Basel, Switzerland; British Columbia Cancer Agency, University of British Columbia, Vancouver, BC, Canada.
PD13-06 Neoadjuvant giredestrant (GDC-9545) + palbociclib versus anastrozole + palbociclib in postmenopausal women with estrogen receptor-positive, HER2-negative, untreated early breast cancer: Primary analysis of the randomized, open-label, phase II coopERA breast cancer study
Hurvitz SA, Quiroga V, Park YH, Bardia A, López-Valverde V, Steinseifer J, Fernando TM, Spera G, Xue C, Fasching PA. University of California, Los Angeles/Jonsson Comprehensive Cancer Center, Los Angeles, CA; GEICAM Spanish Breast Cancer Group, San Sebastián de los Reyes, Madrid, Spain; Samsung Medical Center, Seoul, Republic of Korea; Massachusetts General Hospital, Harvard Medical School, Boston, MA; F. Hoffmann-La Roche Ltd, Basel, Switzerland; Genentech, Inc., South San Francisco, CA; Translational Research in Oncology (TRIO), Montevideo, Uruguay; F. Hoffmann-La Roche Ltd, Toronto, ON, Canada; University Hospital Erlangen, Comprehensive Cancer Center (CCC) Erlangen-EMN, Friedrich-Alexander University Erlangen-Nürnberg, Erlangen, Germany.
PD13-07 Activity and biomarker analyses from a phase Ia/b study of giredestrant (GDC-9545; G) with or without palbociclib (palbo) in patients with estrogen receptor-positive, HER2-negative locally advanced/metastatic breast cancer (ER+/HER2- LA/mBC)
Presenter: Elgene Lim Turner NC, Loi S, Moore HM, Chang C-W, Eng-Wong J, Bardia A, Boni V, Sohn J, Jhaveri KL, Lim E. Royal Marsden Hospital, London, United Kingdom; Peter MacCallum Cancer Centre, Melbourne, Australia; Genentech, Inc., South San Francisco, CA; Massachusetts General Hospital Cancer Center, Boston, MA; START Madrid-CIOCC, Centro Integral Oncologico Clara Campal, HM Hospitales Sanchinarro, Madrid, Spain; Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea; Memorial Sloan Kettering Cancer Center, New York, NY; Garvan Institute of Medical Research, St Vincent's Clinical School, Faculty of Medicine, UNSW Sydney, Darlinghurst, Australia.
PD13-08 First-in-human safety and activity of ARV-471, a novel PROTAC® estrogen receptor degrader, in ER+/HER2- locally advanced or metastatic breast cancer
Hamilton E, Vahdat L, Han HS, Ranciato J, Gedrich R, Keung CF, Chirnomas D, Hurvitz S. Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN; MSK Physicians at Norwalk Hospital, Norwalk, CT; Moffitt Cancer Center, Tampa, FL; Arvinas, Inc., New Haven, CT; UCLA, Santa Barbara, CA.
PD13-09 Primary analysis from NEOS trial: A randomized phase III study that assessed the long-term prognosis of estrogen receptor positive (ER+) primary breast cancer (PBC) pts who received neoadjuvant endocrine therapy (NET) with/without adjuvant chemotherapy (CT)
Iwata H, Toyama T, Taira N, Masuda N, Yamamoto Y, Fujisawa T, Ohtani S, Kashiwaba M, Sakai T, Hasegawa Y, Nakamura R, Akabane H, Shibahara Y, Sasano H, Yamaguchi T. Aichi Cancer Center Hospital, Nagoya, Japan; Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan; Okayama University Hospital, Okayama, Japan; National Hospital Organization Osaka National Hospital, Osaka, Japan; Kumamoto University, Kumamoto, Japan; Gunma Prefectural Cancer Center, Ota, Japan; Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan; Adachi Breast Clinic, Kyoto, Japan; Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan; Hirosaki Municipal Hospital, Hirosaki, Japan; Chiba Cancer Center, Chiba, Japan; Hokkaido P.W.F.A.C. Asahikawa-Kosei General Hospital, Asahikawa, Japan; Tohoku University School of Medicine, Sendai, Japan.
PD13-10 Extended adjuvant endocrine therapy in a longitudinal cohort of young breast cancer survivors
Sella T, Zheng Y, Rosenberg SM, Ruddy KJ, Gelber SI, Tamimi RM, Peppercorn JM, Schapira L, Borges VF, Come SE, Carey LA, Winer EP, Partridge AH. Dana Farber Cancer Institute, Boston, MA; Weill Cornell Medicine, New York, NY; Mayo Clinic, Rochester, MN; Massachusetts General Hospital, Boston, MA; Stanford Cancer Institute, Palo Alto, CA; University of Colorado Comprehensive Cancer Center, Aurora, CO; Beth Israel Deaconess Medical Center, Boston, MA; University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC.